The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease

Masaki Fujita, Akira Kajiki, Yoshiaki Tao, Masayuki Miyazaki, Hiroshi Ouchi, Eiji Harada, Satoshi Ikegame, Takemasa Matsumoto, Junji Uchino, Kentaro Watanabe, Yoichi Nakanishi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Despite recent advances in chemotherapy, the treatment of pulmonary Mycobacterium avium complex (MAC) disease remains unsatisfactory. Judging from its MIC, fluoroquinolones including gatifloxacin (GFLX) are expected to demonstrate efficacy against MAC disease. However, there have been few clinical studies using fluoroquinolones. Therefore, a prospective study to evaluate the clinical efficacy and safety of a fluoroquinolone-containing regimen for the treatment of pulmonary MAC disease was conducted. In this trial, patients with pulmonary MAC disease received protocol-guided combined chemotherapy with rifampin (RFP) and ethambutol (EB) plus either GFLX or clarithromycin (CAM). Adult patients who fulfilled the criteria of the ATS definition of pulmonary MAC disease were enrolled in this study. The patients provided their informed consent, and treatments were administered for 1 year. Of 27 patients enrolled from three facilities, 14 patients were treated with the CAMcontaining regimen and 13 patients were treated with the GFLX-containing regime. Four patients did not complete the 1-year treatment because of adverse events. Nine patients (64.3%) in the CAM group and 11 patients (84.6%) in the GFLX group achieved eradication of pathogens. Adverse events were observed more frequently in the GFLX group than in the CAM group. However, there were no severe adverse events in either group. The longterm results showed a similar relapse rate between the CAM and GFLX groups. The fluoroquinolone-containing regimen demonstrated both high efficacy and relative safety for pulmonary MAC disease that was similar to that of the CAM-containing regimen, which is considered to be the standard regimen.

Original languageEnglish
Pages (from-to)146-151
Number of pages6
JournalJournal of Infection and Chemotherapy
Volume18
Issue number2
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Mycobacterium avium Complex
Fluoroquinolones
Clarithromycin
Safety
Lung
Drug Therapy
Ethambutol
Therapeutics
Rifampin
Informed Consent
gatifloxacin
Prospective Studies
Recurrence

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease. / Fujita, Masaki; Kajiki, Akira; Tao, Yoshiaki; Miyazaki, Masayuki; Ouchi, Hiroshi; Harada, Eiji; Ikegame, Satoshi; Matsumoto, Takemasa; Uchino, Junji; Watanabe, Kentaro; Nakanishi, Yoichi.

In: Journal of Infection and Chemotherapy, Vol. 18, No. 2, 04.2012, p. 146-151.

Research output: Contribution to journalArticle

Fujita, M, Kajiki, A, Tao, Y, Miyazaki, M, Ouchi, H, Harada, E, Ikegame, S, Matsumoto, T, Uchino, J, Watanabe, K & Nakanishi, Y 2012, 'The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease', Journal of Infection and Chemotherapy, vol. 18, no. 2, pp. 146-151. https://doi.org/10.1007/s10156-011-0303-5
Fujita, Masaki ; Kajiki, Akira ; Tao, Yoshiaki ; Miyazaki, Masayuki ; Ouchi, Hiroshi ; Harada, Eiji ; Ikegame, Satoshi ; Matsumoto, Takemasa ; Uchino, Junji ; Watanabe, Kentaro ; Nakanishi, Yoichi. / The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease. In: Journal of Infection and Chemotherapy. 2012 ; Vol. 18, No. 2. pp. 146-151.
@article{a717472c1f324c2d955d82b156d9e067,
title = "The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease",
abstract = "Despite recent advances in chemotherapy, the treatment of pulmonary Mycobacterium avium complex (MAC) disease remains unsatisfactory. Judging from its MIC, fluoroquinolones including gatifloxacin (GFLX) are expected to demonstrate efficacy against MAC disease. However, there have been few clinical studies using fluoroquinolones. Therefore, a prospective study to evaluate the clinical efficacy and safety of a fluoroquinolone-containing regimen for the treatment of pulmonary MAC disease was conducted. In this trial, patients with pulmonary MAC disease received protocol-guided combined chemotherapy with rifampin (RFP) and ethambutol (EB) plus either GFLX or clarithromycin (CAM). Adult patients who fulfilled the criteria of the ATS definition of pulmonary MAC disease were enrolled in this study. The patients provided their informed consent, and treatments were administered for 1 year. Of 27 patients enrolled from three facilities, 14 patients were treated with the CAMcontaining regimen and 13 patients were treated with the GFLX-containing regime. Four patients did not complete the 1-year treatment because of adverse events. Nine patients (64.3{\%}) in the CAM group and 11 patients (84.6{\%}) in the GFLX group achieved eradication of pathogens. Adverse events were observed more frequently in the GFLX group than in the CAM group. However, there were no severe adverse events in either group. The longterm results showed a similar relapse rate between the CAM and GFLX groups. The fluoroquinolone-containing regimen demonstrated both high efficacy and relative safety for pulmonary MAC disease that was similar to that of the CAM-containing regimen, which is considered to be the standard regimen.",
author = "Masaki Fujita and Akira Kajiki and Yoshiaki Tao and Masayuki Miyazaki and Hiroshi Ouchi and Eiji Harada and Satoshi Ikegame and Takemasa Matsumoto and Junji Uchino and Kentaro Watanabe and Yoichi Nakanishi",
year = "2012",
month = "4",
doi = "10.1007/s10156-011-0303-5",
language = "English",
volume = "18",
pages = "146--151",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease

AU - Fujita, Masaki

AU - Kajiki, Akira

AU - Tao, Yoshiaki

AU - Miyazaki, Masayuki

AU - Ouchi, Hiroshi

AU - Harada, Eiji

AU - Ikegame, Satoshi

AU - Matsumoto, Takemasa

AU - Uchino, Junji

AU - Watanabe, Kentaro

AU - Nakanishi, Yoichi

PY - 2012/4

Y1 - 2012/4

N2 - Despite recent advances in chemotherapy, the treatment of pulmonary Mycobacterium avium complex (MAC) disease remains unsatisfactory. Judging from its MIC, fluoroquinolones including gatifloxacin (GFLX) are expected to demonstrate efficacy against MAC disease. However, there have been few clinical studies using fluoroquinolones. Therefore, a prospective study to evaluate the clinical efficacy and safety of a fluoroquinolone-containing regimen for the treatment of pulmonary MAC disease was conducted. In this trial, patients with pulmonary MAC disease received protocol-guided combined chemotherapy with rifampin (RFP) and ethambutol (EB) plus either GFLX or clarithromycin (CAM). Adult patients who fulfilled the criteria of the ATS definition of pulmonary MAC disease were enrolled in this study. The patients provided their informed consent, and treatments were administered for 1 year. Of 27 patients enrolled from three facilities, 14 patients were treated with the CAMcontaining regimen and 13 patients were treated with the GFLX-containing regime. Four patients did not complete the 1-year treatment because of adverse events. Nine patients (64.3%) in the CAM group and 11 patients (84.6%) in the GFLX group achieved eradication of pathogens. Adverse events were observed more frequently in the GFLX group than in the CAM group. However, there were no severe adverse events in either group. The longterm results showed a similar relapse rate between the CAM and GFLX groups. The fluoroquinolone-containing regimen demonstrated both high efficacy and relative safety for pulmonary MAC disease that was similar to that of the CAM-containing regimen, which is considered to be the standard regimen.

AB - Despite recent advances in chemotherapy, the treatment of pulmonary Mycobacterium avium complex (MAC) disease remains unsatisfactory. Judging from its MIC, fluoroquinolones including gatifloxacin (GFLX) are expected to demonstrate efficacy against MAC disease. However, there have been few clinical studies using fluoroquinolones. Therefore, a prospective study to evaluate the clinical efficacy and safety of a fluoroquinolone-containing regimen for the treatment of pulmonary MAC disease was conducted. In this trial, patients with pulmonary MAC disease received protocol-guided combined chemotherapy with rifampin (RFP) and ethambutol (EB) plus either GFLX or clarithromycin (CAM). Adult patients who fulfilled the criteria of the ATS definition of pulmonary MAC disease were enrolled in this study. The patients provided their informed consent, and treatments were administered for 1 year. Of 27 patients enrolled from three facilities, 14 patients were treated with the CAMcontaining regimen and 13 patients were treated with the GFLX-containing regime. Four patients did not complete the 1-year treatment because of adverse events. Nine patients (64.3%) in the CAM group and 11 patients (84.6%) in the GFLX group achieved eradication of pathogens. Adverse events were observed more frequently in the GFLX group than in the CAM group. However, there were no severe adverse events in either group. The longterm results showed a similar relapse rate between the CAM and GFLX groups. The fluoroquinolone-containing regimen demonstrated both high efficacy and relative safety for pulmonary MAC disease that was similar to that of the CAM-containing regimen, which is considered to be the standard regimen.

UR - http://www.scopus.com/inward/record.url?scp=84863304346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863304346&partnerID=8YFLogxK

U2 - 10.1007/s10156-011-0303-5

DO - 10.1007/s10156-011-0303-5

M3 - Article

C2 - 21927844

AN - SCOPUS:84863304346

VL - 18

SP - 146

EP - 151

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 2

ER -